BMO Capital Maintains Outperform on Chemours, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst John McNulty maintains an Outperform rating on Chemours (NYSE:CC) and raises the price target from $30 to $32.
October 07, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has reaffirmed its Outperform rating on Chemours and increased the price target from $30 to $32, indicating a positive outlook.
The reaffirmation of an Outperform rating and an increased price target by BMO Capital suggests confidence in Chemours' future performance, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100